Pathfinder Cell Therapy, Inc. (PFND)
- Previous Close
0.0000 - Open
0.0000 - Bid --
- Ask --
- Day's Range
0.0000 - 0.0000 - 52 Week Range
0.0000 - 0.0001 - Volume
500 - Avg. Volume
0 - Market Cap (intraday)
2.001M - Beta (5Y Monthly) -30.44
- PE Ratio (TTM)
∞ - EPS (TTM)
0.0000 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Pathfinder Cell Therapy, Inc., a development stage regenerative medicine company, focuses on developing novel cell-derived and related therapies for the treatment of various diseases and medical conditions characterized by organ-specific cell damage. It identifies diabetes, renal disease, myocardial infarction, peripheral vascular disease, and other diseases as potential indications for therapies based on its technology. The company was founded in 2008 and is headquartered in Cambridge, Massachusetts.
www.pathfindercelltherapy.comRecent News: PFND
View MorePerformance Overview: PFND
Trailing total returns as of 5/20/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PFND
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PFND
View MoreValuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-888.76%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-1.08M
Diluted EPS (ttm)
0.0000
Balance Sheet and Cash Flow
Total Cash (mrq)
4k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-223k